FTC Approves Amgen’s Acquisition of Horizon

The FTC's continued scrutiny of pharmaceutical deals suggests that companies might be more cautious when pursuing mergers and acquisitions, particularly large transactions, to avoid regulatory challenges. FTC Chair Lina Khan emphasized the agency's commitment to addressing practices that raise drug prices, limit access, hinder innovation, or harm patients, signaling ongoing antitrust scrutiny in the industry.